JP2025505673A - Ｃｏｖｉｄ感染症を処置するための方法および組成物 - Google Patents

Ｃｏｖｉｄ感染症を処置するための方法および組成物 Download PDF

Info

Publication number
JP2025505673A
JP2025505673A JP2024547086A JP2024547086A JP2025505673A JP 2025505673 A JP2025505673 A JP 2025505673A JP 2024547086 A JP2024547086 A JP 2024547086A JP 2024547086 A JP2024547086 A JP 2024547086A JP 2025505673 A JP2025505673 A JP 2025505673A
Authority
JP
Japan
Prior art keywords
peptide
mutations
compound
linker
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505673A5 (https=
Inventor
ペンテルート、ブラッドリー
ヒブナー、バーバラ、エル．
Original Assignee
デコイ セラピューティクス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デコイ セラピューティクス、インコーポレイテッド filed Critical デコイ セラピューティクス、インコーポレイテッド
Publication of JP2025505673A publication Critical patent/JP2025505673A/ja
Publication of JP2025505673A5 publication Critical patent/JP2025505673A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024547086A 2022-02-07 2023-02-07 Ｃｏｖｉｄ感染症を処置するための方法および組成物 Pending JP2025505673A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263307371P 2022-02-07 2022-02-07
US63/307,371 2022-02-07
US202217870174A 2022-07-21 2022-07-21
US202217870158A 2022-07-21 2022-07-21
US17/870,174 2022-07-21
US17/870,158 2022-07-21
PCT/US2023/012488 WO2023150375A2 (en) 2022-02-07 2023-02-07 Methods and compositions for treating covid infections

Publications (2)

Publication Number Publication Date
JP2025505673A true JP2025505673A (ja) 2025-02-28
JP2025505673A5 JP2025505673A5 (https=) 2026-02-03

Family

ID=87552901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547086A Pending JP2025505673A (ja) 2022-02-07 2023-02-07 Ｃｏｖｉｄ感染症を処置するための方法および組成物

Country Status (4)

Country Link
EP (1) EP4475868A2 (https=)
JP (1) JP2025505673A (https=)
CN (1) CN119156396A (https=)
WO (1) WO2023150375A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) * 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551813A (ja) * 2019-09-04 2022-12-14 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 麻疹に対する併用抗ウイルス療法
US20230285539A1 (en) * 2020-03-06 2023-09-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against sars-cov-2 and other coronaviruses
AU2021244228A1 (en) * 2020-03-25 2022-11-17 Biohaven Therapeutics Ltd. Technologies for preventing or treating infections
WO2021207517A2 (en) * 2020-04-10 2021-10-14 Sapience Therapeutics, Inc. Modified hr2 peptide inhibitors of coronavirus fusion
US11180534B1 (en) * 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
WO2023150375A3 (en) 2023-10-19
EP4475868A2 (en) 2024-12-18
CN119156396A (zh) 2024-12-17
WO2023150375A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US20250387468A1 (en) Methods and Compositions for Treating Infections
KR20220079860A (ko) 신규 펩티드
CN106456707B (zh) 干粉肽药剂
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
ES2927948T3 (es) Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo
US20230270756A1 (en) LIPOSOMAL FORMULATIONS FOR INHIBITING SARS-CoV-2 REPLICATION AND REDUCING LUNG INFLAMMATION
JP5465182B2 (ja) ポリアルキレンイミンを含むウイルス感染症治療薬
TW202017939A (zh) 貽貝黏著蛋白的抗病毒用途
JP2025505673A (ja) Ｃｏｖｉｄ感染症を処置するための方法および組成物
US20240108735A1 (en) Methods and compositions for treating covid infections
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
US20260077052A1 (en) Methods For Reducing Or Preventing SARS-COV-2 Infection And Transmission
WO2025231157A2 (en) New anti-viral therapeutic peptides, conjugates, and methods of use thereof
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
EP4720093A2 (en) Methods for making peptide conjugates and the product made therefrom
EP4359009A1 (en) Griffithsin for use in a method of preventing or treating infections with respiratory viruses
ES3002532T3 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
US20250009896A1 (en) Supramolecular filaments based viral particle capture for prevention and therapy of viral infection
EP4269424A1 (en) Novel antiviral compounds and use thereof
CN117529329A (zh) 治疗呼吸窘迫的组合物和方法
WO2025231182A9 (en) New formulation of antiviral peptide conjugates
HK40104234A (zh) 治疗呼吸窘迫的组合物和方法
JP2023526499A (ja) ウイルス性内皮炎を処置するためのｂベータ－１５－４２

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260126